GSK’s chief scientific officer is jumping ship, dealing a blow to the drugmaker as it seeks to rebuild its pipeline of new medicines and gears up for a corporate split in the summer.
Hal Barron, the highly regarded US scientist and veteran of Roche and Genentech, was one of the GSK chief executive Emma Walmsley’s key hires a few months after she took the helm in April 2017.
